Monalizumab: inhibiting the novel immune checkpoint NKG2A

Monalizumab: inhibiting the novel immune checkpoint NKG2A

Abstract The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, allevia...

Full description

Bibliographic Details
Main Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer immunotherapy
CD8 T cells
NK cells
NKG2A
Inhibitory immune receptor
HLA-E/Qa-1
Online Access:http://link.springer.com/article/10.1186/s40425-019-0761-3

Internet

http://link.springer.com/article/10.1186/s40425-019-0761-3

Similar Items